A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is being done to assess mogamulizumab-associated rash in patients diagnosed with mycosis fungoides or sezary syndrome and treated with standard of care mogamulizumab. One of the most common side effects of mogamulizumab is a rash, currently named mogamulizumab-associated rash (MAR) which can look like MF or SS. However, mogamulizumab-associated rash (MAR) does not indicate failure of mogamulizumab, and may be a sign that the drug is working. If not properly evaluated, mogamulizumab-associated rash (MAR) could be misinterpreted as worsening of mycosis fungoides/sezary syndrome, which could lead doctors to recommend stopping mogamulizumab treatment early. The information learned by doing this research study may help tell the difference between mogamulizumab-associated rash (MAR) (sometimes also called "drug eruption") and worsening of the disease. It may also help to uncover information about the cause of mogamulizumab-associated rash (MAR).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dorosły pacjent (wiek 18 lat lub więcej)
- •Rozpoznanie nawracającego lub opornego na leczenie chłoniaka grzybiaka skóry (stadium IB-IV) lub zespołu Sezary'ego
- •Nowo rozpoczęte leczenie mogamulizumabem
- •Podpisana zgoda na udział w badaniu
- •Gotowość do pobrania próbki tkanki na początku badania
- •Gotowość do oddania próbki krwi na początku badania i w razie potrzeby podczas leczenia
✗ Disqualifies
- •Równoczesne leczenie innymi systemowymi lekami na chłoniaka skóry (oprócz maści sterydowych)
- •Wcześniejsze leczenie mogamulizumabem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (10)
City of Hope Medical Center
Duarte, United States
Stanford Cancer Institute Palo Alto
Palo Alto, United States
Moffitt Cancer Center
Tampa, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, United States
Brigham and Women's Hospital
Boston, United States
Siteman Cancer Center at Washington University
St Louis, United States
Thomas Jefferson University Hospital
Philadelphia, United States
M D Anderson Cancer Center
Houston, United States
Fred Hutchinson Cancer Center
Seattle, United States
Trial contact
Christiane Querfeld
Christiane Querfeld
PRINCIPAL_INVESTIGATOR
Youn H. Kim
Youn H. Kim
PRINCIPAL_INVESTIGATOR
Pei-Ling Chen
Pei-Ling Chen
PRINCIPAL_INVESTIGATOR
Pamela B. Allen
Pamela B. Allen
PRINCIPAL_INVESTIGATOR
Sima Rozati
Sima Rozati
PRINCIPAL_INVESTIGATOR
Cecilia A. Larocca
Cecilia A. Larocca
PRINCIPAL_INVESTIGATOR
Neha Mehta Shah
Neha Mehta Shah
PRINCIPAL_INVESTIGATOR
Neda Nikbakht
Neda Nikbakht
PRINCIPAL_INVESTIGATOR
Auris Huen
Auris Huen
PRINCIPAL_INVESTIGATOR
Michi M. Shinohara
Michi M. Shinohara
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.